Puma Biotechnology Inc (PBYI.N)

PBYI.N on New York Stock Exchange

224.08USD
21 Nov 2014
Price Change (% chg)

$2.36 (+1.06%)
Prev Close
$221.72
Open
$225.19
Day's High
$226.39
Day's Low
$221.70
Volume
24,413
Avg. Vol
44,876
52-wk High
$278.50
52-wk Low
$42.12

PBYI.N

Chart for PBYI.N

About

Puma Biotechnology, Inc. is a development-stage biopharmaceutical company that acquires and develops products for the treatment of various forms of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to... (more)

Overall

Beta: --
Market Cap (Mil.): $6,684.42
Shares Outstanding (Mil.): 30.15
Dividend: --
Yield (%): --

Financials

Search Stocks

Puma Biotech says cancer drug fails mid-stage study

- Puma Biotechnology Inc said its cancer drug failed as a primary treatment for breast cancer patients in a mid-stage study, sending its shares down 14 percent in extended trading.

14 Nov 2014

UPDATE 1-Puma Biotech says cancer drug fails mid-stage study

Nov 13 - Puma Biotechnology Inc said its cancer drug failed as a primary treatment for breast cancer patients in a mid-stage study, sending its shares down 14 percent in extended trading.

14 Nov 2014

Puma Biotech says cancer drug fails mid-stage study

Nov 13 - Puma Biotechnology Inc said its experimental breast cancer drug failed in a mid-stage study, sending its shares down 14 percent in extended trading.

14 Nov 2014

Healthcare sector sees silver lining in U.S. tax inversion rules

NEW YORK - Investors and bankers have been lamenting the potential death of large cross-border healthcare mergers since the U.S. Treasury Department announced in late September that it would curtail the tax breaks from international deals designed to give U.S. companies a legal home in a low-tax country.

07 Nov 2014

DEALTALK-Healthcare sector sees silver lining in U.S. tax inversion rules

NEW YORK, Nov 6 - Investors and bankers have been lamenting the potential death of large cross-border healthcare mergers since the U.S. Treasury Department announced in late September that it would curtail the tax breaks from international deals designed to give U.S. companies a legal home in a low-tax country.

07 Nov 2014

Puma Biotechnology cancer drug shows positive mid-stage results

- Puma Biotechnology Inc said its experimental lung cancer drug was safe to be administered with an already approved treatment for the disease in a mid-stage study.

29 Sep 2014

Puma Biotechnology cancer drug shows positive mid-stage results

Sept 29 - Puma Biotechnology Inc said its experimental lung cancer drug was safe to be administered with an already approved treatment for the disease in a mid-stage study.

29 Sep 2014

L'Oreal, Puma sign licence agreement for beauty products

PARIS, Sept 26 - French cosmetics giant L'Oreal said on Friday it had signed a licence agreement for beauty products with Germany's Puma that will become effective on Jan. 1.

26 Sep 2014

Puma renews sponsorship deal with Czech soccer FA

BERLIN, Sept 8 - German sportswear company Puma said it has renewed its partnership with the Czech Republic Football Association, extending a sponsorship deal that has been running since 1995.

08 Sep 2014

Earnings vs. Estimates

Search Stocks